Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Maurie Markman; William Kelly


Cancer Treatment Centers of America has appointed Maurie Markman as president of its medicine and science unit. Previously, Markman was senior VP of clinical affairs and national director of medical oncology at CTCA.

In his new position, Markman will lead CTCA's national clinical team. He is an expert in the field of medical oncology and clinical research, and has conducted “pioneering work” in advanced genomic testing, CTCA CEO Gerard van Grinsven said in a statement. Throughout his career, Markman has held various leadership roles at many leading cancer institutions, including The Cleveland Clinic, the University of Texas MD Anderson Cancer Center, and The Ohio State University.

Exosome Diagnostics has appointed William Kelly as its chief financial officer, effective May 27. Kelly has two decades of financial management experience and spent 13 years leading life sciences firms. He served as chief financial officer of RepliGen Corporation since 2008. Before that, Kelly was corporate controller of Haemonetics Corporation.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.